Wu Capital

Wu Capital operates as an investment company. It invests in technology, media, telecom (TMT), healthcare, fintech, high-tech, offline experience consumptions, virtual experience consumptions, culture and Sports, and other related fields. Wu Capital operates business worldwide. It has its headquarters in Beijing in China.

Rita Zhang

CEO

42 past transactions

Nuvig Therapeutics

Series B in 2024
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

Ray Therapeutics

Series A in 2023
Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.

Rona Therapeutics

Series A in 2022
Rona Therapeutics is an RNA therapeutics platform focused on the discovery, development, and commercialization of innovative RNA medicines. The company specializes in modular and programmable RNA therapies, offering services that encompass oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics aims to create transformative RNA treatments that can significantly alter disease management across various therapeutic areas. To achieve this, the company is developing advanced facilities to enhance nucleic acid synthesis, delivery systems, oligonucleotide chemical modification, and RNA biology. By fostering an environment that promotes innovation, Rona Therapeutics is dedicated to improving patient outcomes and supporting healthier, longer lives.

Korro Bio

Series B in 2022
Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

RiVAI

Series A in 2021
RiVAI Technologies specializes in the development of advanced RISC-V based CPUs and customized System-on-Chip (SoC) designs. The company focuses on delivering high-performance computing solutions for diverse applications, ranging from edge computing to data centers. Additionally, RiVAI develops artificial intelligence chips tailored for Internet of Things (IoT) applications, catering to various sectors such as wearable technology, smart homes, security systems, agriculture, and consumer electronics. By offering low-power yet high-performance core processor chips, RiVAI enables its clients to meet the growing demands of modern computing environments.

Ranok Therapeutics

Series B in 2021
Ranok Therapeutics is a biotechnology company focused on developing targeted protein degradation technology to discover and create new therapeutics. This innovative approach engages various biological processes and demonstrates superiority over existing targeted protein degradation methods. The company's pipeline includes both well-established and novel drug targets associated with cancer and other diseases that present significant unmet medical needs. Ranok is committed to advancing the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Feiliu

Series A in 2021
Feiliu Technology is a clothing supply chain service company based in Shanghai, China, established in 2016 by a team of scientists from IBM's Dr. Watson. It specializes in providing clothing solutions to factories, designers, and brand customers by leveraging artificial intelligence technology. Feiliu focuses on connecting various stakeholders in the garment industry, including fabric suppliers, garment factories, industrial workers, and e-commerce platforms. This integration aims to create an efficient and continuous supply chain service, enhancing optimization and management within the sector. As a national high-tech enterprise, Feiliu is dedicated to advancing the application of AI in the clothing supply chain.

Laiye

Series C in 2021
Laiye is a digital workforce platform that enhances organizational productivity by integrating AI Agents and intelligent automation capabilities. The platform offers tools for robotic process automation (RPA) and intelligent document processing (IDP), enabling businesses to streamline operations and improve outcomes. Laiye's automation process platform simulates human tasks, allowing for the automatic processing of emails and documents, generating reports, and managing data entry in customer relationship management systems. By leveraging these technologies, Laiye helps enterprises increase efficiency and reduce operational costs.

Gemini Therapeutics

Post in 2021
Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.

Medbanks

Series E in 2020
Medbanks Network Technology, founded in 2014 and based in Beijing, specializes in data processing services for the healthcare sector. The company focuses on developing an oncology database that compiles clinical and professional medical service information gathered from hospitals. This resource aims to enhance the understanding and management of cancer care. In addition, Sipai Health Technology Co Ltd operates within the medical technology and health management space in China, encompassing three main segments: specialty pharmacy, physician research assistance, and health insurance services. The specialty pharmacy segment is the primary revenue driver, while the company predominantly conducts its business within the People's Republic of China.

Inipharm

Series A in 2020
Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases.

Deptrum

Funding Round in 2020
Deptrum Limited, founded in 2018 by three scientists from Silicon Valley, specializes in developing optical technology and 3D vision solutions. Headquartered in Shanghai, with an additional location in Shenzhen, the company offers a full-stack solution that encompasses both hardware and software, leveraging nanophotonics and artificial intelligence to enhance machine perception of the 3D world. Deptrum's proprietary technology is designed for diverse applications across multiple sectors, including intelligent terminals, augmented and virtual reality, intelligent security, robotics, and automated medical devices. Their innovations include the world's first non-VCSEL structured light solution, which powers a variety of AIoT devices, such as mobile robots and AR devices, enabling enhanced interaction with the environment.

Korro Bio

Series A in 2020
Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Citrine Medicine

Series A in 2020
Citrine Medicine is a rare disease-focused pharmaceutical firm.

Akouos

Series B in 2020
Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Laiye

Series C in 2020
Laiye is a digital workforce platform that enhances organizational productivity by integrating AI Agents and intelligent automation capabilities. The platform offers tools for robotic process automation (RPA) and intelligent document processing (IDP), enabling businesses to streamline operations and improve outcomes. Laiye's automation process platform simulates human tasks, allowing for the automatic processing of emails and documents, generating reports, and managing data entry in customer relationship management systems. By leveraging these technologies, Laiye helps enterprises increase efficiency and reduce operational costs.

PACT Pharma

Series C in 2020
PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment, specifically through neoantigen-specific adoptive T-cell therapies aimed at solid tumors. The company utilizes bioinformatics to analyze the DNA and RNA of patients' tumors and normal tissues, identifying candidate neoantigen peptides that can stimulate targeted antitumor T-cell responses. By recognizing unique neo-epitopes associated with individual cancers, PACT Pharma enables the engineering of autologous T cells designed to specifically target and eliminate tumor cells expressing these neoantigens. Founded in 2016 and based in South San Francisco, California, PACT Pharma is dedicated to advancing innovative treatment options for patients with cancer.

Medbanks

Series D in 2019
Medbanks Network Technology, founded in 2014 and based in Beijing, specializes in data processing services for the healthcare sector. The company focuses on developing an oncology database that compiles clinical and professional medical service information gathered from hospitals. This resource aims to enhance the understanding and management of cancer care. In addition, Sipai Health Technology Co Ltd operates within the medical technology and health management space in China, encompassing three main segments: specialty pharmacy, physician research assistance, and health insurance services. The specialty pharmacy segment is the primary revenue driver, while the company predominantly conducts its business within the People's Republic of China.

Loving Care

Series B in 2019
Loving Care International Pet Hospital is a comprehensive animal medical institution that operates a chain of clinics and hospitals focused on pet healthcare services. The facility offers a range of services including beauty treatments, physical examinations, vaccinations, and clinics. In addition to standard medical care, Loving Care provides users with information on the prevention of common diseases in dogs and cats, as well as alternative pet health issues. The establishment also operates mobile animal service vehicles to deliver home-based basic medical services, ensuring that pets receive the care they need in a convenient manner. Through its commitment to improving the diagnosis and treatment of pet diseases, including serious conditions such as tumors, Loving Care aims to enhance the overall well-being of animals and support pet owners in maintaining their pets' health.

Laiye

Series B in 2019
Laiye is a digital workforce platform that enhances organizational productivity by integrating AI Agents and intelligent automation capabilities. The platform offers tools for robotic process automation (RPA) and intelligent document processing (IDP), enabling businesses to streamline operations and improve outcomes. Laiye's automation process platform simulates human tasks, allowing for the automatic processing of emails and documents, generating reports, and managing data entry in customer relationship management systems. By leveraging these technologies, Laiye helps enterprises increase efficiency and reduce operational costs.

Deptrum

Series A in 2019
Deptrum Limited, founded in 2018 by three scientists from Silicon Valley, specializes in developing optical technology and 3D vision solutions. Headquartered in Shanghai, with an additional location in Shenzhen, the company offers a full-stack solution that encompasses both hardware and software, leveraging nanophotonics and artificial intelligence to enhance machine perception of the 3D world. Deptrum's proprietary technology is designed for diverse applications across multiple sectors, including intelligent terminals, augmented and virtual reality, intelligent security, robotics, and automated medical devices. Their innovations include the world's first non-VCSEL structured light solution, which powers a variety of AIoT devices, such as mobile robots and AR devices, enabling enhanced interaction with the environment.

Sanjieke

Series B in 2019
Sanjieke is an online education platform based in China that focuses on providing vocational training and corporate education for IT professionals. The company offers a variety of courses aimed at enhancing professional growth by delivering industry-specific knowledge and skills that are often not available through traditional universities. By catering to the evolving demands of the market, Sanjieke's platform helps individuals develop competencies that are crucial for success in the technology sector.

Cassia Networks

Series B in 2019
Cassia Networks is a wireless telecommunications company specializing in Bluetooth technology aimed at enhancing connectivity within Internet of Things (IoT) applications. Founded in 2014 by Felix Zhao, the company develops innovative solutions to address the challenges of IoT connectivity and management. Its product line includes the Cassia Hub Bluetooth router, which is recognized as the world's first Bluetooth router capable of remotely controlling up to 22 Bluetooth devices over long distances. Other offerings include a Bluetooth smart plug, multi-color LED lights, personal safety sensors, and Bluetooth speakers. With offices in Silicon Valley and Beijing, Cassia Networks strives to simplify IoT integration by allowing users to manage multiple Bluetooth devices from anywhere, overcoming the traditional limitations of short-range controls.

Smart Bees

Series B in 2019
Smart Bees is a developer of innovative foldable furniture designed for small living spaces, primarily targeting consumers in China. The company focuses on creating high-quality, environmentally safe furniture that embodies fashion and simplicity. By prioritizing intelligent design, Smart Bees aims to provide practical solutions for individuals seeking stylish and functional furnishings for compact environments.

Cobo

Series A in 2018
Cobo, established in 2017 and headquartered in Singapore, is a leading provider of digital asset custody solutions catering to institutional clients. The company offers a comprehensive suite of custody technologies, including full custody with bank-grade hardware security modules, co-managed custody utilizing advanced multi-party computation technology, and fully decentralized self-custody based on smart contracts. Cobo also provides additional services such as Wallet-as-a-Service, an off-exchange settlement network called SuperLoop, and on-chain DeFi strategies through its Argus platform. With over 500 institutional clients and billions of dollars in assets under custody, Cobo serves a diverse clientele that includes exchanges, mining pools, and both crypto-native and traditional institutions across multiple continents. Committed to security and regulatory compliance, Cobo holds SOC 2 Type 1 and Type 2 certifications and is licensed in various jurisdictions, including the US, Singapore, and Hong Kong. The company is supported by prominent global investors and completed a significant funding round in September 2021.

Meng Fan Japanese

Series A in 2018
Meng Fan Japanese is an online education platform.

Newtop100.com

Series A in 2018
Newtop100.com is a media and entertainment company based in Beijing, China, founded in 2016. It specializes in publishing news reports and conducting interviews with leaders in the new economy, focusing on innovative technologies and emerging business models. Through various audio and digital media platforms, Newtop100.com provides in-depth coverage and analysis of over 100 leading companies, allowing clients to explore investment opportunities within this dynamic sector. The company aims to highlight pioneers in different domains of the new economy, facilitating informed decisions for investors and stakeholders alike.

Kangaroo Mama

Series A in 2018
Kangaroo Mama is a Shanghai Based Education Start Up.

Roadstar.AI

Series A in 2018
Roadstar.AI is a startup based in Silicon Valley and Shenzhen, founded by experts in robotics and machine learning with backgrounds from prominent tech companies. The company specializes in autonomous driving technology aimed at enhancing transportation systems. Its innovative approach leverages a multi-sensor fusion framework that ensures precise time and spatial synchronization, enabling real-time updates and robust data extraction. By integrating artificial intelligence into vehicles, Roadstar.AI aspires to create safer, more efficient, and enjoyable travel experiences for all users.

Youyang

Series A in 2018
Youyang Media operates an education content sharing platform aimed at parents of children up to twelve years old. Founded in 2016 and based in Beijing, China, the company offers a variety of parenting resources, including personalized childcare knowledge videos, virtual and augmented reality content, and systematic original parenting videos. Its platform also features offline activities designed to enhance parent education and provide growth resources and educational products. By focusing on engaging and informative content, Youyang seeks to support parents in their childcare journey.

Laiye

Series B in 2017
Laiye is a digital workforce platform that enhances organizational productivity by integrating AI Agents and intelligent automation capabilities. The platform offers tools for robotic process automation (RPA) and intelligent document processing (IDP), enabling businesses to streamline operations and improve outcomes. Laiye's automation process platform simulates human tasks, allowing for the automatic processing of emails and documents, generating reports, and managing data entry in customer relationship management systems. By leveraging these technologies, Laiye helps enterprises increase efficiency and reduce operational costs.

Semma Therapeutics

Series B in 2017
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.

Yunding Technology

Series C in 2017
Yunding Network Technology is a developer of smart home security systems, specializing in smart locks in the smart apartment segment under its brands Loock and Yunding.

Liulishuo

Series C in 2017
Liulishuo is a leading artificial intelligence-driven educational technology company founded in September 2012 by Dr. Wang Wei and Dr. Hu Zhe and Dr. Lin Hui. Liulishuo offers a personalized and adaptive language learning experience to 50 million learners in 379 cities in China and over 175 countries around the world. Its self-developed artificial intelligence English teacher, based on deep learning technology, can provide personalized and adaptive learning courses for each user.

Namihe

Series B in 2017
Namihe is a digital textbook and smart reading service platform that offers rich reading content and creates a range of reading settings for kids between the ages of 6 and 15. They provide a learning tool for the school students.
Cui Yutao Health Management Center specializes in the development of a comprehensive health management platform focused on children's physical and mental well-being. The center provides a mobile application that offers daily health records, an online parenting community, and expert guidance for child health management. It also facilitates access to medical assistance and child health insurance services. Through these offerings, parents can obtain valuable information related to childcare, including medical advice, early-stage education, and infant products, thereby enhancing pediatric care and supporting the health needs of children.
Cui Yutao Health Management Center specializes in the development of a comprehensive health management platform focused on children's physical and mental well-being. The center provides a mobile application that offers daily health records, an online parenting community, and expert guidance for child health management. It also facilitates access to medical assistance and child health insurance services. Through these offerings, parents can obtain valuable information related to childcare, including medical advice, early-stage education, and infant products, thereby enhancing pediatric care and supporting the health needs of children.

Apricot Forest

Series C in 2014
Apricot Forest operates a mobile application designed for Chinese doctors, offering access to patient records, medical journals, and discussion boards. The platform aims to enhance the clinical practice by combining scientific resources with a humanistic approach, thereby improving efficiency and productivity in healthcare settings. By facilitating easier access to essential medical information and fostering professional discussions, Apricot Forest seeks to support doctors in delivering high-quality medical care.

XiaoHongChun

Angel Round in 2014
XiaoHongChun, established in April 2015, operates as a fashion and beauty business platform that primarily targets young women. The company is known for its Xiaohonglip app, which focuses on cosmetics video sharing, helping consumers navigate beauty products. In addition to its app, XiaoHongChun engages in internet celebrity brokerage and manages beauty brand operations. The company also facilitates cross-border e-commerce supply chains, enhancing social interactions in the beauty and fashion sectors while offering valuable shopping guidance to its users.

Qianding

Series A in 2014
Qianding is the development of smart cities and communities. They focus on intelligent solutions for communities, parks, businesses, apartments, and other spaces. They provide services like integrated service reconstruction. They offer smart community management, smart access control, and smart community solutions. They empower ecological integration to promote synergy and sustainable development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.